Comparing the current results to its competitors, Cumberland Pharmaceuticals Inc reported Revenue decrease in the 2 quarter 2026 year on year by -98.46 %, despite the revenue increase by the most of its competitors of 19.8 %, recorded in the same quarter.
Cumberland Pharmaceuticals Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 139.65 %
Cumberland Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company operates in a pharmaceutical industry marked by intense competition and rapid innovation. Key competitive factors include product efficacy, safety, ease of use, cost-effectiveness, brand awareness, marketing and distribution capabilities, product access through contracting and partnerships, intellectual property rights, resources for development and commercialization, business development activities, third-party reimbursements, insurance coverage, and collaborations. The company's product Caldolor demonstrated advantages in safety and healthcare utilization compared to its competitor ketorolac in real-world outcomes research. The brand Kristalose faces increased substitution rates due to new generic competitors. The company supports Kristalose through partnerships with Poly Pharmaceuticals and Foxland Pharmaceuticals, Inc. Competitors include other branded products, generics, and alternative medical treatments, some of which possess greater research, development, sales, marketing, and financial resources.
Publicly Traded Peers of Cumberland Pharmaceuticals Inc
Abeona Therapeutics Inc Share Performance
+12.62%
This Year
Abeona Therapeutics Inc
Profile
Abeona Therapeutics Inc is a biopharmaceutical company focused on developing gene and cell therapies for rare genetic diseases. Their business model revolves around identifying and acquiring promising technologies, conducting pre-clinical and clinical research, and eventually bringing these therapies to the market. They collaborate with academic institutions, medical centers, and patient advocacy groups to advance their pipeline and provide solutions for currently untreatable genetic disorders.
Aquestive Therapeutics Inc follows a business model that focuses on the development and commercialization of innovative products to address unmet medical needs. The company primarily operates in the pharmaceutical industry, leveraging its proprietary drug delivery technology to create and improve various medications for patients.
Bausch Health Companies Inc operates through three segments: Bausch + Lomb/International, Salix, and Ortho Dermatologics. The company focuses on developing, manufacturing, and marketing a wide range of pharmaceutical products, medical devices, and over-the-counter products primarily in the areas of eye health, gastroenterology, and dermatology. Bausch Health aims to provide innovative and quality healthcare solutions to improve patients' lives globally.
Collegium Pharmaceutical Inc's business model revolves around the development and commercialization of innovative products specifically designed to address the limitations of existing treatment options in pain management. They focus on developing extended-release formulations that offer abuse-deterrent properties to enhance patient safety and combat prescription drug abuse. By leveraging strategic partnerships, they aim to bring their products to market efficiently and effectively.
Sources:
Cumberland Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cumberland Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
